November 22, 2016 - By Clifton Ray · 0 Comments
Cellular Biomedicine Group Inc (NASDAQ:CBMG) institutional sentiment decreased to 2 in Q2 2016. Its down -2.17, from 4.17 in 2016Q1. The ratio turned negative, as 25 active investment managers opened new and increased positions, while 6 sold and trimmed equity positions in Cellular Biomedicine Group Inc. The active investment managers in our partner’s database now own: 2.46 million shares, up from 1.06 million shares in 2016Q1. Also, the number of active investment managers holding Cellular Biomedicine Group Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 4 Increased: 19 New Position: 6.
Cellular Biomedicine Group, Inc. is a biomedicine company. The company has a market cap of $201.79 million. The Firm is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell technologies. It currently has negative earnings. The Firm operates in Biomedicine Cell Therapy segment.
About 2,095 shares traded hands. Cellular Biomedicine Group Inc (NASDAQ:CBMG) has declined 28.35% since April 20, 2016 and is downtrending. It has underperformed by 32.91% the S&P500.
According to Zacks Investment Research, “Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California.”
Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.01% of its portfolio in Cellular Biomedicine Group Inc for 34,571 shares. American International Group Inc owns 7,000 shares or 0% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 329 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Blackrock Advisors Llc, a Delaware-based fund reported 5,513 shares.#img1#
Cellular Biomedicine Group, Inc. (CBMG), incorporated on January 18, 2013, is a biomedicine company. The Firm is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell technologies. The Firm operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Firm is focused on developing and marketing cell therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
More recent Cellular Biomedicine Group Inc (NASDAQ:CBMG) news were published by: Globenewswire.com which released: “Cellular Biomedicine Group Announces Dismissal of Class Action Litigation” on August 18, 2016. Also Globenewswire.com published the news titled: “Cellular Biomedicine Group Announces CEO Transition” on January 11, 2016. Streetinsider.com‘s news article titled: “Dangdai International Makes $43.1M Strategic Investment in Cellular …” with publication date: April 19, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray